119 related articles for article (PubMed ID: 12807818)
1. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K; O'Mara LA; Allen PM
Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
[TBL] [Abstract][Full Text] [Related]
2. T cell-mediated delay of spontaneous mammary tumor onset: increased efficacy with in vivo versus in vitro activation.
O'Mara LA; Norian LA; Kreamalmeyer D; White JM; Allen PM
J Immunol; 2005 Apr; 174(8):4662-9. PubMed ID: 15814690
[TBL] [Abstract][Full Text] [Related]
3. Eradication of established tumors by CD8+ T cell adoptive immunotherapy.
Hanson HL; Donermeyer DL; Ikeda H; White JM; Shankaran V; Old LJ; Shiku H; Schreiber RD; Allen PM
Immunity; 2000 Aug; 13(2):265-76. PubMed ID: 10981969
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
5. T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
Bruns M; Wanger J; Schumacher U; Deppert W
Oncotarget; 2016 Oct; 7(40):64543-64559. PubMed ID: 27579535
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
Huang H; Liu Y; Xiang J
Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
[TBL] [Abstract][Full Text] [Related]
7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
8. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
9. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells.
Wei WZ; Ratner S; Shibuya T; Yoo G; Jani A
J Immunol Methods; 2001 Dec; 258(1-2):141-50. PubMed ID: 11684131
[TBL] [Abstract][Full Text] [Related]
10. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. Bystander elimination of antigen loss variants in established tumors.
Spiotto MT; Rowley DA; Schreiber H
Nat Med; 2004 Mar; 10(3):294-8. PubMed ID: 14981514
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.
Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H
Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491
[TBL] [Abstract][Full Text] [Related]
14. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.
Bai XF; Liu J; Li O; Zheng P; Liu Y
J Clin Invest; 2003 May; 111(10):1487-96. PubMed ID: 12750398
[TBL] [Abstract][Full Text] [Related]
15. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
16. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
17. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
18. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.
Muraoka D; Nishikawa H; Noguchi T; Wang L; Harada N; Sato E; Luescher I; Nakayama E; Kato T; Shiku H
Vaccine; 2013 Apr; 31(17):2110-8. PubMed ID: 23499606
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary tumors inefficiently prime tumor-specific T cells.
O'Mara LA; Allen PM
J Immunol; 2004 Jan; 172(1):310-7. PubMed ID: 14688339
[TBL] [Abstract][Full Text] [Related]
20. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
